Skip to main content
Premium Trial:

Request an Annual Quote

GenMark Files $150M Shelf Registration

NEW YORK (GenomeWeb News) – GenMark Diagnostics has filed a shelf registration with the US Securities and Exchange Commission to offer from time to time up to $150 million of its stock and/or other securities.

Proceeds from any sale of its securities will go toward general corporate purposes, such as R&D, license or technology acquisitions, menu expansion, and the development of the company's products, GenMark said. Proceeds may also be used for sales and marketing initiatives, commercial expansion, as well as general administrative expenses, working capital, and capital expenditures.

Aside from its common stock, other forms of securities the company may offer include warrants, preferred stock, and debt securities, according to its Form S-3 filed today.

GenMark is based in Carlsbad, Calif., and went public in the US in 2010. It develops molecular diagnostic assays and instruments, and last week reported a sharp increase in fourth-quarter revenues to $9.4 million.

Last June the company raised about $39.3 million in a public offering of its shares.

In afternoon trading on the Nasdaq, shares of GenMark were down around 4 percent at $11.56.

The Scan

Mosquitos Genetically Modified to Prevent Malaria Spread

A gene drive approach could be used to render mosquitos unable to spread malaria, researchers report in Science Advances.

Gut Microbiomes Allow Bears to Grow to Similar Sizes Despite Differing Diets

Researchers in Scientific Reports find that the makeup of brown bears' gut microbiomes allows them to reach similar sizes even when feasting on different foods.

Finding Safe Harbor in the Human Genome

In Genome Biology, researchers present a new approach to identify genomic safe harbors where transgenes can be expressed without affecting host cell function.

New Data Point to Nuanced Relationship Between Major Depression, Bipolar Disorder

Lund University researchers in JAMA Psychiatry uncover overlapping genetic liabilities for major depression and bipolar disorder.